5:04 PM
Nov 07, 2012
 |  BC Extra  |  Top Story

Auxilium, Pfizer ending Xiapex deal

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) and Pfizer Inc. (NYSE:PFE) mutually agreed to terminate a 2008 deal granting the pharma exclusive European and Eurasian commercialization rights to Xiapex collagenase clostridium, effective April 24, 2013. Xiapex is approved in the EU and U.S., where it is known as Xiaflex, to treat Dupuytren's contracture in adult patients with a palpable cord, which affects joints in the hand....

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >